AbbVie taps Umoja for new in vivo CAR-T deal
AbbVie penned two deals with Umoja Biopharma for its in vivo CAR-T cell therapy programs, the companies announced Thursday.
AbbVie gets an option to license Umoja’s lead program, a CD19-directed therapy for blood cancers, under the first agreement. Under the second deal, the two companies will develop up to four in vivo CAR-T therapy candidates for targets chosen by AbbVie.
Umoja received upfront payments and an equity investment from AbbVie, though it declined to share specifics. With both deals added up, Umoja could receive up to $1.44 billion in milestones, plus sales milestones and royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.